Di Maio M, et al: Symptomatic toxicities experienced during anticancer treatment:agreement between patient and physician reporting in three randomized trials. J Clin Oncol, 10, 910-915 (2015)
U.S. Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), Center for Devices and Radiological Health (CDRH):Guidance for Industry-Patient-Reported Outcome Measures : Use in Medical Product Development to Support Labeling Claims (2009) http://www.fda.gov/downloads/Drugs/Guidances/UCM193282.pdf
Eton DT, et al: A combination of distribution-and anchor-based approaches determined minimally important differences (MIDs) for four endpoints in a breast cancer scale. J Clin Epidemiol, 57, 898-910 (2004)